-+ 0.00%
-+ 0.00%
-+ 0.00%

Should You Be Adding Senores Pharmaceuticals (NSE:SENORES) To Your Watchlist Today?

Simply Wall St·11/20/2026 00:14:35
Listen to the news

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story even if these companies are loss-making. Sometimes these stories can cloud the minds of investors, leading them to invest with their emotions rather than on the merit of good company fundamentals. Loss making companies can act like a sponge for capital - so investors should be cautious that they're not throwing good money after bad.

Despite being in the age of tech-stock blue-sky investing, many investors still adopt a more traditional strategy; buying shares in profitable companies like Senores Pharmaceuticals (NSE:SENORES). Even if this company is fairly valued by the market, investors would agree that generating consistent profits will continue to provide Senores Pharmaceuticals with the means to add long-term value to shareholders.

How Fast Is Senores Pharmaceuticals Growing?

Generally, companies experiencing growth in earnings per share (EPS) should see similar trends in share price. That means EPS growth is considered a real positive by most successful long-term investors. Recognition must be given to the that Senores Pharmaceuticals has grown EPS by 37% per year, over the last three years. Growth that fast may well be fleeting, but it should be more than enough to pique the interest of the wary stock pickers.

One way to double-check a company's growth is to look at how its revenue, and earnings before interest and tax (EBIT) margins are changing. The good news is that Senores Pharmaceuticals is growing revenues, and EBIT margins improved by 3.0 percentage points to 24%, over the last year. Both of which are great metrics to check off for potential growth.

The chart below shows how the company's bottom and top lines have progressed over time. To see the actual numbers, click on the chart.

earnings-and-revenue-history
NSEI:SENORES Earnings and Revenue History November 20th 2026

Check out our latest analysis for Senores Pharmaceuticals

While we live in the present moment, there's little doubt that the future matters most in the investment decision process. So why not check this interactive chart depicting future EPS estimates, for Senores Pharmaceuticals?

Are Senores Pharmaceuticals Insiders Aligned With All Shareholders?

It's pleasing to see company leaders with putting their money on the line, so to speak, because it increases alignment of incentives between the people running the business, and its true owners. So it is good to see that Senores Pharmaceuticals insiders have a significant amount of capital invested in the stock. Notably, they have an enviable stake in the company, worth ₹17b. That equates to 33% of the company, making insiders powerful and aligned with other shareholders. So there is opportunity here to invest in a company whose management have tangible incentives to deliver.

Is Senores Pharmaceuticals Worth Keeping An Eye On?

Senores Pharmaceuticals' earnings per share growth have been climbing higher at an appreciable rate. That EPS growth certainly is attention grabbing, and the large insider ownership only serves to further stoke our interest. At times fast EPS growth is a sign the business has reached an inflection point, so there's a potential opportunity to be had here. Based on the sum of its parts, we definitely think its worth watching Senores Pharmaceuticals very closely. We should say that we've discovered 1 warning sign for Senores Pharmaceuticals that you should be aware of before investing here.

There's always the possibility of doing well buying stocks that are not growing earnings and do not have insiders buying shares. But for those who consider these important metrics, we encourage you to check out companies that do have those features. You can access a tailored list of Indian companies which have demonstrated growth backed by significant insider holdings.

Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction.